Article
Therapy of metastatic malignant melanoma: on the way to individualized disease control.
Advances in experimental medicine and biology - 1 Jan 2014
Vogt Thomas
Abstract excerpt
After decades of therapeutic frustration, the identification of some fundamental molecular drivers finally set the stage for the development of targeted therapies of metastatic malignant melanoma. With the invention of B-RAF inhibitors, targeting the mutated and activated B-RAF molecule in the MAP kinase cascade, objective responses can be achieved in about 50% of those cases harbouring this specific mutation....
Topics
- Antibodies
- Antineoplastic Agents
- CTLA-4 Antigen
- Drug Resistance, Neoplasm
- Humans
- Melanoma
- Mutation
- Neoplastic Stem Cells
- Precision Medicine
- Programmed Cell Death 1 Receptor
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins B-raf
- Remission Induction
- Skin Neoplasms
- Melanoma, Cutaneous Malignant